BioWorld

March 24, 2009

View Archived Issues

Morphotek Gets SPA to Start Phase III Ovarian Cancer Trial

After yielding promising interim Phase II data, Morphotek Inc.'s farletuzumab is set to enter a pivotal, Phase III trial in ovarian cancer under a special protocol assessment. (BioWorld Today) Read More

Appeals Court Sides with Feds on GSK Patent Case

Read More

Merck Serono Launches Venture Fund with $54M Commitment

Read More

MDRNA Soars on siRNA Tech Deal with Novartis

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More